In-silico docking, synthesis, structure analysis, DFT calculations, energy frameworks, and pharmacological intervention of [ , , ]-thiadiazoles analogous as XO inhibitor and on multiple molecular inflammatory targets COX and LOX

• Newer [ 1 , 3 , 4 ]-thiadiazoles compounds (7a-j) are synthesized and have been evaluated as XO inhibitor. • Bioactivity were evaluated for inflammatory enzymes using COX and LOX. • Compound (7i) was found to exhibited best activity. • The results were supported by In-silico docking, DFT and MEP surface studies. Xanthine oxidase (XO) is an interesting target for the synergic treatment of several diseases such as gout, hypertension, type 2 diabetes, and kidney disease. Associated complication includes hyperuricemia, which is considered one of the most common metabolic lifestyle disorders worldwide. Overproduction and insufficient excretion of uric acid during purine metabolism results in the formation of uric acid crystals in kidneys, joints, and other tissues. Allopurinol and Febuxostat, a clinically available drug used to reduce XO activity and serum uric acid level, are demonstrated to produce adverse effects including gastrointestinal distress, hypersensitivity, and skin rash, raising safety concerns. Exploring newer and novel XO inhibitors with minimum or no side effects is the aim of the current study. [ 1 , 3 , 4 ]-Thaidiazole analogs (7a-j) scaffold plays an important role in the design of efficient and potent inhibitors. In the present work, (7a-j) were evaluated for their ability to inhibit XO and found that among the series compound (7i) is selected as the best compound for inhibition of XO . Further, cyclooxygenases (COXs) and 5-lipoxygenase (5-LOX), enzymes that generate biologically active lipid molecules termed eicosanoids, are considered inflammatory and play a vital role in inflammatory pathways in the human body. Apart from their relation with inflammation, the additional involvement of COX-2 enzyme with cancer activity was recently discovered. In some cancer types, the level of COX-2 enzyme is increased indicating that this enzyme could be a suitable target for cancer therapy. Based on these findings, we have synthesized some new novel [ 1 , 3 , 4 ]-thiadiazole analogous (7a-j) and tested them against XO, COX, and LOX. To gain insight into the activity of XO, COX, and LOX inhibition, molecular docking studies were carried out for XO, COX, and LOX enzymes utilizing the newly synthesized compounds (7a-j) , and the results inferred that among the synthesized series of [ 1 , 3 , 4 ]-thiadiazoles (7a-j) , the compound (7i) showed extremely good result in both In silico and evaluation studies of XO, COX, and LOX, which is in agreement with the experimental results. Furthermore, density functional theory (DFT) was applied to calculate HOMO-LUMO, energy gap, and other parameters under the hybrid exchange-correlation functional (B3LYP) with the triple split valence basis set (6-311G).